The biggest focus for those in the pharmaceuticals industry moving forward should be to emphasise the importance of proactive adaptability in implementing FAIR data frameworks, and to underscore how making the investment now will pay dividends in years to come.

Digitalisation is the reality for each of us in our private life. In laboratories, it’s still a dream. But why are we dreaming of digitalisation and of connectivity between your instruments and your leading systems when these things are actually at our fingertips? The reason might be obvious: when the right tools to connect all software silos are missing, we can’t be digitalised in reality.

In this Commentary article, we explore some of the applications of synthetic data generation in the context of healthcare and treatment. Synthetic data can overcome problems surrounding privacy and enable the sharing of important medical information without compromising the privacy of patients.

Digital health is often seen as the 'next big thing' but there are challenges ahead. This month, our discussion group focused on fragmentation, data flow, protection and regulatory approval.

On-Demand Webinar featuring Dr Christos Kannas, Associate Principal Scientist at R&D AstraZeneca & Dr Maya Natarajn, Neo4j Senior Director of Knowledge Graphs

Data digitisation has led to a market shift in operability, as well as a strong emphasis on trust and a need for broad standardisation. Zisis Kozlakidis, Head of Laboratory Services and Biobanking at the International Agency for Research on Cancer, sat down with us to discuss current and future trends in digital data governance for healthcare, as well as the need for a coordinated data strategy going forward.

As of 2023, all new clinical trial applications in the EU must be submitted via the Clinical Trials Information System.

RWD now represents a major source of information for understanding current treatment results and improving future analysis. Its proper implementation in healthcare analysis has the potential to improve patient outcomes.

Dr Boris Adryan, Digital & Data Capability Building Lead at Merck Healthcare KGaA, teaches the company’s workforce the importance of data.

This Commentary piece looks at the means by which the global approval process for new medicines can be sped up through the controlled use of FAIR data. Key areas of focus include the sharing of healthcare data to bring the patient voice within the clinical setting.

This Commentary article revisits the development and implementation of mobile health data, exploring how initiatives such as the NHS track and trace system helped to mitigate the worst of the impact of the Covid-19 pandemic. Here, we consider the applications of mHealth data for present and future pandemic situations.